Picard Medical (PMI) Goes Public: SynCardia’s FDA-Approved Total Artificial Heart Poised for Global Expansion

In the United States, whether a 69-meter-high rocket can be recovered determines the cost ceiling of the aerospace industry; while in the intensive care unit, a mechanical heart that can replace two ventricles and four valves determines whether a patient can survive the "valley of death" before transplantation.

SynCardia Systems, LLC has completed more than 2,100 clinical implants, with a cumulative runtime of over millions of hours, and has been applied in 27 countries worldwide. The value behind this is not only about "staying alive" but transforming survival into a replicable and scalable engineering outcome. In contrast, among China's 3 million patients with severe heart failure, only 1,062 can receive donor hearts each year, and the 97% unmet demand further highlights the scarcity of this technology.

SpaceX Uses 33 Raptor Engines to Lift a "Reusable" Future, Reducing Launch Costs to $1,410/kg; SynCardia Systems, Through 20 Years of Clinical Iterations, Has Increased Pre-Transplant Survival Rates from 46% to 79%. The Logic of Both Is the Same: As Long as Physical Laws Allow, It Can Be Achieved by Engineering; Once Achieved by Engineering, It Can Reshape Industry Standards. SynCardia’s Fully Implantable Artificial Heart, Expected to Be Approved by 2028, Is Like the "Starship" in the Medical Field, Aiming Directly at the Ultimate Form of "Eliminating External Constraints."

If SpaceX has opened up the "space economy," then SynCardia has opened up the "survival economy."

China's 97% heart transplant gap represents the hardest market logic. Global data shows that SynCardia has cumulatively extended over 750 patient-years of life, with a one-year post-transplant survival rate as high as 86%. For Chinese patients, this means the "unattainable" fate can be replaced by what is "manufacturable."

It's not just demand that has attracted capital's attention, but also policy. In 2024, 62 innovative medical devices in Shenzhen entered the special review process, and Beijing accumulated 84 such devices, both running through a “green channel” akin to SpaceX receiving commercial space support from NASA. Combined with the industrial ecosystem—Shenzhen’s speed, Beijing’s depth, and Shanghai’s internationalization—a “medical version of Cape Canaveral” is being built for SynCardia Systems.

Several first-tier cities in China are building their own medical technology hubs through different approaches. Whether it's policy support, clinical resources, or an international ecosystem, all are contributing to the future industrial landscape.

As the city with the highest medical device output value in China for many consecutive years, Shenzhen boasts a mature industrial chain and a highly market-driven mechanism. The approval efficiency here is 40% faster than the national average, accompanied by substantial financial rewards and policy support, providing an "accelerated pathway" from research and development to registration. This highly efficient environment makes it an ideal launchpad for innovative medical device companies.

Relying on authoritative institutions such as Anzhen Hospital, Beijing has accumulated rich experience in the fields of cardiovascular, transplantation, and heart failure management, possessing clinical databases and follow-up systems covering the entire country. For cutting-edge technologies that require long-term validation and large-scale data support, Beijing's research and medical environment is almost irreplaceable.

As China's most international medical device hub, Shanghai hosts the headquarters of foreign-funded enterprises, with Zhangjiang Park nurturing benchmark cases that have gone global. Relying on the precision manufacturing and biomaterials supply chain in the Yangtze River Delta, Shanghai not only possesses full-chain capabilities in R&D and production but also helps companies directly access the global market.

In the past, the industry brought "heartbeat" from the laboratory to the operating table, crossing the thresholds from prototype to mass production and from individual cases to routine practice; now, TAH has been built into a reliable "bridge," turning weeks of uncertainty into months of stable waiting that can be sustained at home. Looking to the future,The roadmap is pointing towards a "fully implantable total artificial heart."(Fully Implantable TAH)": Truly integrating "complete heart replacement" inside the human body, eliminating reliance on external wires and an external main unit; reducing the burden outside the hospital, lowering infection risks, making the system quieter and more reliable, and allowing for long-term stable operation that adapts to the patient’s condition. More importantly, the goal is not just to prolong the "waiting for a transplant," but to remove "waiting" from the equation altogether — using a mass-producible, fully implantable total artificial heart that can be followed up on, directly taking over the role previously fulfilled by donor hearts, becoming a long-term alternative solution that doesn't rely on transplantation, enabling patients to live long, stable lives at home, even without a donor.

In other words, SynCardia's entry into China is not merely a market expansion but a decision that defines the future of the medical ecosystem. By 2028, when the fully implantable artificial heart receives approval in the United States, whether China can simultaneously usher in this new era will largely depend on today’s location choices and policies. Just as SpaceX’s reusable rockets revolutionized the aerospace industry, SynCardia’s "entry into China" could become the pivotal leap that transforms the global landscape of heart treatment.